Drugs / UP421
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06239636 | Mar 2024 → May 2025 overdue | type 1 diabetes mellitus | Per-Ola Carlsson | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UP421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239636 ↗ |
| Modality | Cell therapy | “composed of genetically modified human pancreatic islet cells” NCT06239636 ↗ |
| Route | Intramuscular | “Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells” NCT06239636 ↗ |